Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study. [PDF]
J Diabetes, 2022 Highlights In this ESCAPE‐extension study, cilostazol treatment reduced the incidence of adverse cardiovascular events in patients with type 2 diabetes when compared with aspirin for a 5.2‐year median follow‐up. During the follow‐up period, no adverse events were noted in the cilostazol group that exceeded those in the aspirin group.
Sohn M, Chun EJ, Lim S.
europepmc +2 more sources
Journal of Diabetes, Volume 13, Issue 8, Page 640-647, August 2021., 2021 Highlights A nested, nationwide, propensity‐matched cohort study was carried out using the Clinical Practice Research Datalink with 1186 patients with no past history of ASCVD, half of whom had undergone bariatric surgery. Bariatric surgery was associated with improved ASCVD outcomes and lower mortality, highlighting a potential prognostic role of the ...
Maddalena Ardissino +6 more
wiley +1 more source
Forensic Pathological Diagnosis of Acute and Old Myocardial Infarction Using Fourier Transform Infrared Spectroscopy [PDF]
, 2023 Objective Fourier transform infrared spectroscopy （FTIR） was used to analyze myocardial infarction tissues at different stages of pathological change to achieve the forensic pathology diagnosis of acute and old myocardial infarction. Methods FTIR spectra
Tian TIAN, Xin-biao LIAO, Fu ZHANG, Kai-fei DENG, Ji ZHANG, Ping HUANG, Yi-jiu CHEN, Jian-hua ZHANG
core +1 more source
Correlation between FAR and severity of coronary artery lesions in patients with premature coronary artery disease [PDF]
, 2023 Objective To investigate the association between fibrinogen/albumin ratio （FAR） and the severity of coronary artery lesions in patients with premature coronary artery disease （PCAD）.
Nurmaimaiti Ying, Wufur Ma
core +1 more source
Correlation analysis of Egr3， IL-6， TNF-α and the severity of coronary heart disease [PDF]
, 2023 Objective To investigate the correlation between early growth response factor 3（Egr3）， pro-inflammatory cytokines IL-6 and TNF-α and coronary atherosclerotic heart disease （CHD）.
Wang Siqing, Zumureti·Abudukeyimu, Li Xia
core +1 more source
Deep Learning-Based Cardiac Imaging Data Measurement and Its Application in Diagnosis of Sudden Cardiac Death [PDF]
, 2021 In the field of forensic medicine, diagnosis of sudden cardiac death is limited by subjective factors and manual measurement methods, so some parameters may have estimation deviation or measurement deviation.
LI Ze-hao, LIU Ning-guo, DONG He-wen, et al.
core +1 more source
Application of OCT in the Forensic Pathological Diagnosis of Coronary Artery Atherosclerosis and Myocardial Infarction [PDF]
, 2019 Objective To investigate the value of optical coherence tomography （OCT） in the diagnosis of coronary atherosclerosis and myocardial infarction in forensic identification.
LI Yang, ZHANG Ning, WANG Cheng-ming，et al.
core +1 more source
Application of Targeted Coronary Angiography in the Diagnosis of Sudden Cardiac Death [PDF]
, 2023 Objective To diagnose coronary artery stenosis by using the postmortem computed tomography angiography （PMCTA）, and to explore the diagnostic value of PMCTA in sudden cardiac death.
Xin ZHAO, Zhi-ming CHEN, Wen-yun LIU, Bo WANG, Hong-yang LI, Li-yao YANG, Yan TENG, Li-jun WANG, Yan-bin GAO, Wei-long CHEN, Lei ZHANG
core +1 more source
Evidence-Based Complementary and Alternative Medicine, Volume 2015, Issue 1, 2015., 2015 Phlegm is one of the most common patterns of coronary artery disease (CAD) in Chinese medicine. Our research was aimed at investigating the association between phlegm syndrome of CAD and coronary angiography (CAG) by meta‐analysis. According to inclusion criteria, a total of 30 studies involving 5,055 CAD patients were included.
Qiu-Yan Zhang +6 more
wiley +1 more source
Application of evolocumab in patients with coronary heart disease complicated with mild renal insufficiency [PDF]
, 2023 Objective To evaluate the efficacy and safety of evolocumab， a proprotein convertase subtilisin/kexin type 9 （PCSK9） inhibitor， in lowering LDL-C levels in patients with coronary heart disease complicated with mild renal insufficiency.
Zhang Yu, Wu Bin, Feng Jiaxu, Wang Rutao, Yuan Ming
core +1 more source